See the Cosentyx dosing schedule and summary of product characteristics.
PsA, AS and nr-axSpA dosing: give your Cosentyx patients the ease of a monthly maintenance schedule1
Cosentyx, alone or in combination with MTX, is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate.
*PsA patients initiated on 150 mg can be increased to 300 mg based on clinical response.
Cosentyx is indicated for the treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.
For patients with active AS, the recommended dose is 150 mg by subcutaneous injection. AS patients initiated on 150 mg can be increased to 300 mg based on clinical response.
Cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation (CRP and/or MRI evidence) in adults who have responded inadequately to non-steroidal anti-inflammatory drugs.
For patients with active nr-axSpA, the recommended dose is 150 mg by subcutaneous injection.
Supporting your Cosentyx patients virtually
We have now digitised our patient packs, leaflets, dosing charts and more. Make sure you can continue to support your Cosentyx patients virtually by exploring our patient resources.
More product information
This link will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.
AS, ankylosing spondylitis; CRP, C-reactive protein; DMARD, disease-modifying anti-rheumatic drug; MRI, magnetic resonance imaging; MTX, methotrexate; nr-axSpA, non-radiographic axial spondyloarthritis; PsA, psoriatic arthritis; SC, subcutaneous; TNF, tumour necrosis factor.
- Cosentyx Summary of Product Characteristics.